BioSpace News Archive

Dr. Palaniappan joins Aruvant from Sarepta where he oversaw technical operations and was responsible for the development and registration of a portfolio of more than 30 compounds including gene therapies for rare diseases

Annual Awards Program Recognizes Outstanding Health & Medical Technology Products and Companies

The Company has Surpassed its Previous Monthly Record, of $19,062.25 in E-Commerce Sales, Posted During April 2020

Emergent and HHS expand 2012 CIADM public-private partnership with task order valued at approximately $628 million for rapid domestic production of leading COVID-19 vaccine candidates through 2021

First patients have been dosed in a Phase 1 study of LY-CoV555, the lead antibody from Lilly’s collaboration with AbCellera

Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer’s disease (AD), Parkinson’s disease (PD) and other neurodegenerative diseases, will hold its 2020 Annual Meeting of Stockholders in a virtual meeting format on Wednesday, June 3, 2020 at 10:00 a.m. (Eastern Time) at www.viewproxy.com/AnnovisBio/2020/VM . Shareholders of record that attend the Annual Meeting will be able to vote and submit ques

Taltz is now approved to treat patients across the full axSpA spectrum, including ankylosing spondylitis (AS), also known as radiographic axSpA, and nr-axSpA

Conference call and live webcast scheduled for Monday, June 1st, 2020 at 8:30 am EDT

Freitag will continue as member of board of directors and serve as special counsel in transitional role through October

Altimmune, Inc., a clinical-stage biopharmaceutical company, announced the U.S. Food and Drug Administration has authorized the Company to proceed with a clinical trial of T-COVID, an investigational agent for the treatment of early COVID-19.